A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
NCT06004336Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnoza raka nerki z komponentem przejrzystych komórek
- •Wiek co najmniej 18 lat
- •Chory jest w dobrym stanie ogólnym (może być całkowicie aktywny lub mieć ograniczenia w pracy)
- •Maksymalnie 5 ognisk przerzutów raka w ciele
- •Przynajmniej jedno ognisko można leczyć radioterapią
- •Prawidłowe wyniki badań krwi i funkcji narządów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Chad Tang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.